INIA Biosciences develops non-invasive, home-administered medical devices that utilize ultrasound technology to modulate the immune system for managing chronic inflammatory diseases. By providing a closed-loop system for real-time monitoring and treatment, INIA aims to enhance patient autonomy and improve health outcomes.
Funding
$200K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MIFounders
Product
Problem
Chronic inflammatory diseases often require frequent monitoring and treatment adjustments, which can be inconvenient and costly for patients. Current treatment options may also have systemic side effects, impacting overall quality of life.
Solution
INIA Biosciences is developing non-invasive, home-administered medical devices that use ultrasound technology to modulate the immune system for managing chronic inflammatory diseases. Their approach provides a closed-loop system, enabling real-time monitoring and treatment adjustments based on the patient's physiological response. By using sound waves to modulate the immune system, INIA aims to offer a targeted therapy with potentially fewer systemic side effects, enhancing patient autonomy and improving health outcomes. The device is designed for ease of use in a home setting, promoting patient compliance and continuous disease management.
Target Audience
The primary target audience includes individuals suffering from chronic inflammatory diseases seeking non-invasive, home-based treatment options, and healthcare providers looking for innovative tools to manage these conditions.
Features
- Non-invasive treatment using focused ultrasound to modulate immune response.
- Home-administered device for convenient and continuous therapy.
- Closed-loop system for real-time monitoring and personalized treatment adjustments.